AstraZeneca has halted a Phase III trial of an experimental lung cancer treatment after an independent review found it was unlikely to deliver the benefits researchers had hoped for.
The eVOLVE-Lung02 trial was studying volrustomig, the experimental drug in question, combined with chemotherapy as a first-line treatment for patients with metastatic non-small cell lung cancer. The trial was for people whose tumours do not express the PD-L1 protein, which doctors use to help determine how likely some cancers are to respond to immunotherapy.
The independent monitoring committee stated that the combination would probably miss both of the study’s two main...